HomeCompareTMBBY vs ABBV

TMBBY vs ABBV: Dividend Comparison 2026

TMBBY yields 9.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TMBBY wins by $350117.34M in total portfolio value
10 years
TMBBY
TMBBY
● Live price
9.67%
Share price
$9.05
Annual div
$0.88
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350117.44M
Annual income
$343,299,655,861.94
Full TMBBY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TMBBY vs ABBV

📍 TMBBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTMBBYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TMBBY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TMBBY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TMBBY
Annual income on $10K today (after 15% tax)
$822.22/yr
After 10yr DRIP, annual income (after tax)
$291,804,707,482.65/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TMBBY beats the other by $291,804,686,426.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TMBBY + ABBV for your $10,000?

TMBBY: 50%ABBV: 50%
100% ABBV50/50100% TMBBY
Portfolio after 10yr
$175058.77M
Annual income
$171,649,840,316.85/yr
Blended yield
98.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TMBBY
No analyst data
Altman Z
0.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TMBBY buys
0
ABBV buys
0
No recent congressional trades found for TMBBY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTMBBYABBV
Forward yield9.67%3.06%
Annual dividend / share$0.88$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$350117.44M$102.3K
Annual income after 10y$343,299,655,861.94$24,771.77
Total dividends collected$349655.46M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TMBBY vs ABBV ($10,000, DRIP)

YearTMBBY PortfolioTMBBY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,635$1,934.63$11,550$430.00+$1.1KTMBBY
2$18,088$4,568.85$13,472$627.96+$4.6KTMBBY
3$31,580$12,225.83$15,906$926.08+$15.7KTMBBY
4$73,688$39,897.63$19,071$1,382.55+$54.6KTMBBY
5$252,859$174,012.39$23,302$2,095.81+$229.6KTMBBY
6$1,386,668$1,116,109.56$29,150$3,237.93+$1.36MTMBBY
7$12,924,308$11,440,573.29$37,536$5,121.41+$12.89MTMBBY
8$213,138,840$199,309,830.33$50,079$8,338.38+$213.09MTMBBY
9$6,371,761,705$6,143,703,146.14$69,753$14,065.80+$6371.69MTMBBY
10$350,117,440,887$343,299,655,861.94$102,337$24,771.77+$350117.34MTMBBY

TMBBY vs ABBV: Complete Analysis 2026

TMBBYStock

TMBThanachart Bank Public Company Limited, together with its subsidiaries, provides various commercial banking products and services to individuals, small and medium sized enterprises (SME), and corporate customers primarily in Thailand. It operates through Commercial Banking and Retail Banking segments. The company offers basic, current, cash concentration, corporate liquidity, term and foreign currency deposit, multi-currency, and savings accounts; working capital, personal, home, auto, credit card, long-term, unsecured, and other loans, as well as special funding programs for SME, letter of guarantee, and supply chain solutions; and debit, credit, and corporate cards. It also provides trade finance, foreign exchange and currency, financial management, hire purchase, finance leasing, bancassurance, and mutual funds, asset management, insurance brokerage, investment banking and advisory, import and export trading, payment, collection, liquidity management, capital market risk management, agency, and other financial services. In addition, the company offers wealth banking, mobile and Internet banking services; mutual funds; and business and properties protection, life and health, personal accident, motor, and travel insurance products. As of December 31, 2021, it operated 636 branches; 3,043 ATMs; and 598 CDMs. The company was formerly known as TMB Bank Public Company Limited and changed its name to TMBThanachart Bank Public Company Limited in May 2021. TMBThanachart Bank Public Company Limited was founded in 1957 and is headquartered in Bangkok, Thailand.

Full TMBBY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TMBBY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TMBBY vs SCHDTMBBY vs JEPITMBBY vs OTMBBY vs KOTMBBY vs MAINTMBBY vs JNJTMBBY vs MRKTMBBY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.